


Display problems? [Open this email in your web browser.](#)



Upgraded: TATAA GrandPerformance SARS-CoV-2 Detection kit (CE-IVD)

The new version has improved protocol with exceptional reproducibility and an Lod of less than 10 molecules. The kit has been validate for the Lightcycler 480, QuantStudio 5 and 6, CFX 96 and 384, more instruments are being added. Compatibility with magnetic bead and cartridge extraction has been verified. New positive control is a long transcript produced separate from primers and probes, which eliminates risk for contamination. Negative samples are truly negative exhibiting no Cq.



Kit includes:

- qPCR probe-based assay for SARS-CoV-2 RdRP-gene (96 rxn)
- CoV RdRP-gene positive control
- RNA Extraction Control
- qPCR probe-based assay for RNA Extraction Control (96 rxn)
- TATAA One-Step Advanced GrandMaster® Mix (1 x 96 rxn)

TATAA Webinars in Association with Swift Biosciences

SWIFT SARS-COV-2 AMPLICON PANEL: NGS IN A SNAP

Date: June 16, 2020

Time: 8:00 am EDT or 14:00 CET time

Speakers: Dr. Jon Irish, Swift Biosciences, Director of Data Sciences

Dr. Kayla Peck, Swift Biosciences, Senior R&D Scientist

The emergence of SARS-CoV-2 has resulted in the need for NGS strategies for characterizing the viral genome. Sequencing of the full-length genome is critical for identifying mutational variants and contributing to research in the fields of virology, immunology, epidemiology, and molecular evolution, among others. However, maximizing viral RNA sequencing reads from clinical specimens can be challenging, particularly due to the amount of human background that may be present. In this webinar, we present a targeted NGS strategy which features the new [Swift Normalase™ Amplicon Panel \(SNAP\)](#) workflow using a SARS-CoV-2 specific panel. The SNAP SARS-CoV-2 kit shows high yields and data quality across a wide range of viral copy numbers, facilitating confident mutation detection from low input samples. The SNAP single-tube workflow allows you to go from cDNA to a normalized library pool, providing an efficient, cost-effective, and high-throughput-friendly approach for your SARS-CoV-2 NGS research.



- TATAA Biocenter launches its first product based on proprietary Direct Blood Genotyping (DBG) technology allowing Point of Care SNP testing. The test is for the sport gene [ACTN3](#). First to offer ACTN3 field genotyping using DBG is Health and Lifestyle company [LifeTest](#).
- An EU funded project ([CoronaDX](#)) developing three Point of Care (POC) devices with participation from TATAA has now started. A national grant from [Vinnova](#) has been received to validate one of the platforms in collaboration with the Research Institutes of Sweden, Sahlgrenska University and Denmark's Technical University (DTU).
- [CANCER-ID](#) consortium publishes "[Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis](#)". Two-Tailed PCR assays for miRNAs are available from [Biovendor](#).
- We are supporting Swedish travelers to countries requiring covid-19 test. Testing is performed by collaborating care units including [Gendoktorn](#) and [Hedda Care](#) who issue certificates.
- Our local newspaper Göteborgsposten recently visited us and Life Genomics: [Read more>](#)

[Services - better results, faster](#)

[High-quality products](#)

[Hands-on trainings](#)



f in

[Unsubscribe](#) | [Manage your subscription](#)
Odinsgatan 28 | SE-411 03 | Gothenburg